Zhixin Cyrillus Tan

Zhixin Cyrillus Tan

Auto-generated profile, based on publicly available information

Zhixin Cyrillus Tan

Bioinformatics Interdepartmental Program, UCLA, Los Angeles, CA 90024

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Science Signaling
Verified
Journal Article
Closed access
SMSimon Mitchell
Simon Mitchell
RTRachel Tsui
Rachel Tsui
ZTZhixin Cyrillus Tan
Zhixin Cyrillus Tan
APArran Pack
Arran Pack
AHAlexander Hoffmann
Alexander Hoffmann
The nuclear factor κB (NF-κB) system is critical for various biological functions in numerous cell types, including the inflammatory response, cell proliferation, survival, differentiation, and pathogenic responses. Each cell type is characterized by a subset of 15 NF-κB dimers whose activity is regulated in a stimulus-responsive manner. Numerous studies have produced different mathematical models that account for cell type–specific NF-κB activities. However, whereas the concentrations or abundances of NF-κB subunits may differ between cell types, the biochemical interactions that constitute the NF-κB signaling system do not. Here, we synthesized a consensus mathematical model of the NF-κB multidimer system, which could account for the cell type–specific repertoires of NF-κB dimers and their cell type–specific activation and cross-talk. Our review demonstrates that these distinct cell type–specific properties of NF-κB signaling can be explained largely as emergent effects of the cell type–specific expression of NF-κB monomers. The consensus systems model represents a knowledge base that may be used to gain insights into the control and function of NF-κB in diverse physiological and pathological scenarios and that describes a path for generating similar regulatory knowledge bases for other pleiotropic signaling systems.

1 September 2021 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
ZTZhixin Cyrillus Tan
Zhixin Cyrillus Tan
MMMadeleine C Murphy
Madeleine C Murphy
HAHakan S Alpay
Hakan S Alpay
STScott D Taylor
Scott D Taylor
AMAaron S Meyer
Aaron S Meyer
Systems serology provides a broad view of humoral immunity by profiling both the antigen‐binding and Fc properties of antibodies. These studies contain structured biophysical profiling across disease‐relevant antigen targets, alongside additional measurements made for single antigens or in an antigen‐generic manner. Identifying patterns in these measurements helps guide vaccine and therapeutic antibody development, improve our understanding of diseases, and discover conserved regulatory mechanisms. Here, we report that coupled matrix–tensor factorization (CMTF) can reduce these data into consistent patterns by recognizing the intrinsic structure of these data. We use measurements from two previous studies of HIV‐ and SARS‐CoV‐2‐infected subjects as examples. CMTF outperforms standard methods like principal components analysis in the extent of data reduction while maintaining equivalent prediction of immune functional responses and disease status. Under CMTF, model interpretation improves through effective data reduction, separation of the Fc and antigen‐binding effects, and recognition of consistent patterns across individual measurements. Data reduction also helps make prediction models more replicable. Therefore, we propose that CMTF is an effective general strategy for data exploration in systems serology.

9 October 2021 in Mathematical Biosciences
Verified
Journal Article
Open access
ZTZhixin Cyrillus Tan
Zhixin Cyrillus Tan
AMAaron S. Meyer
Aaron S. Meyer
Multivalent cell surface receptor binding is a ubiquitous biological phenomenon with functional and therapeutic significance. Predicting the amount of ligand binding for a cell remains an important question in computational biology as it can provide great insight into cell-to-cell communication and rational drug design toward specific targets. In this study, we extend a mechanistic, two-step multivalent binding model. This model predicts the behavior of a mixture of different multivalent ligand complexes binding to cells expressing various types of receptors. It accounts for the combinatorially large number of interactions between multiple ligands and receptors, optionally allowing a mixture of complexes with different valencies and complexes that contain heterogeneous ligand units. We derive the macroscopic predictions and demonstrate how this model enables large-scale predictions on mixture binding and the binding space of a ligand. This model thus provides an elegant and computationally efficient framework for analyzing multivalent binding.

21 December 2021 in Integrative Biology
Verified
Journal Article
Closed access
PDF file
ZTZhixin Cyrillus Tan
Zhixin Cyrillus Tan
BOBrian T Orcutt-Jahns
Brian T Orcutt-Jahns
AMAaron S Meyer
Aaron S Meyer
A critical property of many therapies is their selective binding to target populations. Exceptional specificity can arise from high-affinity binding to surface targets expressed exclusively on target cell types. In many cases, however, therapeutic targets are only expressed at subtly different levels relative to off-target cells. More complex binding strategies have been developed to overcome this limitation, including multi-specific and multivalent molecules, creating a combinatorial explosion of design possibilities. Guiding strategies for developing cell-specific binding are critical to employ these tools. Here, we employ a uniquely general multivalent binding model to dissect multi-ligand and multi-receptor interactions. This model allows us to analyze and explore a series of mechanisms to engineer cell selectivity, including mixtures of molecules, affinity adjustments, valency changes, multi-specific molecules and ligand competition. Each of these strategies can optimize selectivity in distinct cases, leading to enhanced selectivity when employed together. The proposed model, therefore, provides a comprehensive toolkit for the model-driven design of selectively binding therapies.

11 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ZTZhixin Cyrillus Tan
Zhixin Cyrillus Tan
AMAaron S. Meyer
Aaron S. Meyer
Multivalent cell surface receptor binding is a ubiquitous biological phenomenon with functional and therapeutic significance. Predicting the amount of ligand binding for a cell remains an important question in computational biology as it can provide great insight into cell-to-cell communication and rational drug design toward specific targets. In this study, we extend a mechanistic, two-step multivalent binding model. This model predicts the behavior of a mixture of different multivalent ligand complexes binding to cells expressing various types of receptors. It accounts for the combinatorially large number of interactions between multiple ligands and receptors, optionally allowing a mixture of complexes with different valencies and complexes that contain heterogeneous ligand units. We derive the macroscopic predictions and demonstrate how this model enables large-scale predictions on mixture binding and the binding space of a ligand. This model thus provides an elegant and computationally efficient framework for analyzing multivalent binding.

27 November 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ZTZhixin Cyrillus Tan
Zhixin Cyrillus Tan
BOBrian Orcutt-Jahns
Brian Orcutt-Jahns
AMAaron S. Meyer
Aaron S. Meyer
A critical property of many therapies is their selective binding to specific target populations. Exceptional specificity can arise from high-affinity binding to unique cell surface targets. In many cases, however, therapeutic targets are only expressed at subtly different levels relative to off-target cells. More complex binding strategies have been developed to overcome this limitation, including multi-specific and multi-valent molecules, but these create a combinatorial explosion of design possibilities. Therefore, guiding strategies for developing cell-specific binding are critical to employ these tools. Here, we extend a multi-valent binding model to multi-ligand and multi-receptor interactions. Using this model, we explore a series of mechanisms to engineer cell selectivity, including mixtures of molecules, affinity adjustments, and valency changes. Each of these strategies maximizes selectivity in distinct cases, leading to synergistic improvements when used in combination. Finally, we identify situations in which selectivity cannot be derived through passive binding alone to highlight areas in need of new developments. In total, this work uses a quantitative model to unify a comprehensive set of design guidelines for engineering cell-specific therapies. Summary points Affinity, valency, and other alterations to target cell binding provide enhanced selectivity in specific situations. Evidence for the effectiveness and limitations of each strategy are abundant within the drug development literature. Combining strategies can offer enhanced selectivity. A simple, multivalent ligand-receptor binding model can help to direct therapeutic engineering.